Leaflet: information for the user
ilviGrip Expectorant powder for oral solution
paracetamol / guaifenesin / phenylephrine hydrochloride
Read this leaflet carefully before you start taking this medicine, as it contains important information for you.
Follow exactly the administration instructions for the medicine contained in this leaflet or those indicated by your doctor or pharmacist.
1. What is ilviGrip Expectorant and what it is used for
2. What you need to know before starting to take ilviGrip Expectorant
3. How to take ilviGrip Expectorant
4. Possible side effects
5. Storage of ilviGrip Expectorant
6. Contents of the pack and additional information
ilviGrip Expectorante contains three active ingredients:
ilviGrip Expectorante is indicated for the short-term relief of symptoms of catarrhal and influenza processes (mild to moderate pain, fever, nasal congestion, with expectorant effect on productive cough) in adults and adolescents 12 years and older.
Only use ilviGrip Expectorante if you have a combination of cold and flu symptoms, such as pain and/or fever, nasal congestion, and productive cough.
Consult your doctor if you do not improve or worsen after 3 days.
Do not takeilviGrip Expectorante:
Warnings and precautions
Important: Contains Paracetamol.Do not take it with other medications that contain paracetamol.
In case of overdose, consult your doctor immediately, even if you feel well, due to the risk of late severe liver damage. Do not take this medication with other medications for the flu, cold, or nasal congestion.
Consult your doctor or pharmacist before takingilviGrip Expectorante:
During treatment with ilvigrip expectorant, immediately inform your doctor if:
You have severe diseases, such as severe renal insufficiency or sepsis (when bacteria and their toxins circulate in the blood, causing damage to organs), or if you have malnutrition, chronic alcoholism, or are also taking flucloxacillin (an antibiotic). A severe disease called metabolic acidosis (a blood and fluid anomaly) has been reported in patients in these situations when using paracetamol at regular doses for a prolonged period or when taking paracetamol with flucloxacillin. Symptoms of metabolic acidosis may include: severe respiratory difficulty with deep and rapid breathing, drowsiness, feeling unwell (nausea), and vomiting.
Children and adolescents
ilviGrip Expectorante is not intended for children under 12 years old.
Use ofilviGrip Expectorantewith other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Inform your doctor if you are taking:
Taking ilviGrip Expectorante with food, drinks, and alcohol
Do not take this product with alcoholic beverages.
Pregnancy, breastfeeding, and fertility
The use of ilviGrip Expectorante during pregnancy and breastfeeding should only be used if recommended by your doctor or pharmacist.
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication. If necessary and only if recommended by a doctor or pharmacist, ilviGrip Expectorante may be used during pregnancy. This product should only be used during breastfeeding under medical supervision. Use the lowest possible dose that reduces your pain and/or fever and use it for the shortest possible time. Contact your doctor if the pain and/or fever do not decrease or if you need to take the medication more frequently.
Driving and operating machines
This medication may cause dizziness or confusion. If you experience drowsiness or dizziness, do not drive or operate machines.
ilviGrip Expectorantecontains aspartame, saccharose, and sodium:
Follow exactly the medication administration instructions contained in this leaflet or those indicated by your doctor or pharmacist.
In case of doubt, ask your doctor or pharmacist.
The recommended dose is:
Adults and adolescents 12 years and older:
The recommended dose is one sachet, which can be taken up to four times a day as needed, with an interval of at least 4 hours between doses. Do not take more than 4 sachets in 24 hours.
Do not exceed the indicated dose.
Use in children and adolescents
This medication should not be used in children under 12 years.
Administration form
This medication is a powder that dissolves in water and is taken hot.
Dissolve the contents of one sachet in a cup with hot water, but not boiling (approx. 250 ml). Let cool until a temperature that can be drunk.
Treatment duration
If symptoms worsen or persist for more than 3 days, consult your doctor.
If you take moreilviGrip Expectorantthan you should
Consult your doctor immediatelyif you accidentally take more than you should or if the medication was accidentally ingested by a child,even if you or the child feels well, due to the risk of late severe liver damage.
In case of overdose or accidental ingestion, go immediately to a medical center, or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount taken.
If you forgot to takeilviGrip Expectorant
Do not take a double dose to compensate for the missed doses.
If you have any other questions about the use of this medication, ask your pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. If you experience any of the following serious side effects, stop taking the medicine immediately and seek urgent medical help.
Frequency | Side effect |
Common (may affect up to 1 in 10 people) | Loss of appetite, nausea, or vomiting |
Rare (may affect fewer than 1 in 1,000 people) | Mild allergic reactions (such as skin rashes or urticaria) Stomach pain, diarrhea Headache, dizziness Fast or irregular heartbeat (palpitations), High blood pressure, Difficulty sleeping (insomnia), Nervousness, Trembling (shivering), Irritability, Restlessness, Confusion, or Anxiety. . Changes in blood tests that measure liver function, Icterus. |
Very rare (may affect up to 1 in 10,000 people) | Severe reduction in blood cells, increasing the risk of infections. |
Unknown frequency (cannot be estimated from available data): | A severe disease that can make the blood more acidic (designated metabolic acidosis) in patients with severe disease who use paracetamol (see section 2). |
Reporting of side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: http;//www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine
Keep this medication out of the sight and reach of children.
Do not store at a temperature above 25°C.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Duration after reconstitution: The reconstituted solution is stable for 90 minutes.
Medicines should not be disposed of through drains or in the trash. Dispose of the containers and medicines you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. In this way, you will help protect the environment.
Composition of GripaVicks
The active principles are paracetamol, guaifenesina and hydrochloride phenylephrine.Each sachet of this medication provides a single dose containing the followingactive principles: 500 mg of paracetamol, 200 mg of guaifenesina and 10 mg of hydrochloride phenylephrine.
Theother components(excipients) are: sucrose, citric acid, tartaric acid, sodium cyclamate, sodium citrate, aspartame (E951), potassium acesulfame (E950), powdered menthol aroma, lemon aroma, lemon juice aroma, yellow quinoline (E104). See end of section 2.
Appearance of the product and contents of the packaging
GripaVicks Expectorant is a white powder that is presented in single-dose sachets in a cardboard box, which is packaged in a box of 5 or 10 sachets.
Not all packaging sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Vicks Laboratories, S.L.U.
Avda. de Bruselas, 24, 28108, Alcobendas, Madrid
Spain
Responsible for manufacturing
Procter & Gamble Manufacturing GmbH
Procter & Gamble Strasse 1
64521Gross-Gerau, Hessen
Germany
Local representative
Procter & Gamble España, S.A.U.
Avenida de Bruselas, 24, 28108 Alcobendas, Madrid
Date of the last review of this prospectus:January 2025
“Detailed information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/”
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.